Linoladiol N (Estradiol Hemihydrate)

Estradiol hemihydrate is a form of estrogen that binds to estrogen receptors (ERα and ERβ) inside cells. The hormone‑receptor complex then moves to the cell nucleus and regulates the transcription of genes that control vaginal tissue health, bone remodeling, and other estrogen‑dependent processes.

The specific dose and treatment schedule for Linoladiol N are determined by the prescribing clinician based on the patient’s medical condition, severity of symptoms, and response to therapy. Patients should follow the prescriber’s instructions and not alter the dose on their own.

The safety of Linoladiol N in pregnancy or lactation has not been established. Estrogen products are generally contraindicated during pregnancy because they may affect fetal development, and they are usually avoided while breastfeeding unless clearly indicated by a healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Linoladiol N contains estradiol hemihydrate, a potent natural estrogen, and is delivered vaginally for local effect with minimal systemic exposure. Compared with conjugated estrogen creams or estriol preparations, estradiol provides a more direct replacement of the primary estrogen, often resulting in quicker symptom relief while maintaining a comparable safety profile when used as directed.

Linoladiol N should be stored at room temperature, below 25 °C (77 °F). Keep the product in its original packaging, protect it from moisture, excessive heat and direct sunlight to maintain stability and potency.

Linoladiol N is a vaginal formulation that is inserted into the vagina using the supplied applicator or as directed by the prescriber. The product is designed for local absorption, and patients should follow the administration instructions provided with the medication or by their healthcare professional.

Serious risks, although rare, include thromboembolic events such as deep‑vein thrombosis or pulmonary embolism, endometrial hyperplasia or carcinoma if systemic absorption is significant, severe allergic reactions, and liver function abnormalities. Patients should report any unusual symptoms promptly to their healthcare provider.

Linoladiol N is contraindicated in women with a history of estrogen‑dependent cancers (e.g., breast or endometrial cancer), active or past thromboembolic disease, unexplained vaginal bleeding, or known hypersensitivity to estradiol or any excipients in the formulation. It should also be avoided in pregnant or breastfeeding women unless specifically advised by a physician.